chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Legs will go numb and tingle. They throb as well. Standing for too long will cause the patient to feel they are going to fall over and need to sit down. The numb and tingle creeps up his back as well. This has been a daily occurrence.  About 11/3 patient described a numb feeling and throb in his arms similar to the feeling in his legs. this went down to his fingers. This only happened the one time. Patient stated he wasn't sure if it was just because of the cold.
Woke up with swelling the size of ping pong ball underneath injection site and itching and redness at site appearing one week after first dose. Swelling decreased throughout day and itchiness disappeared with use of ice packs, but swelling and some redness is still ongoing
still has the rash; received 1st dose years ago, didn´t get the 2nd; got Shingles; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a elderly male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix and did not receive 2nd dose of Shingrix. In August 2022, several years after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles. On an unknown date, the patient experienced rash and incomplete course of vaccination. On an unknown date, the outcome of the shingles and incomplete course of vaccination were unknown and the outcome of the rash was not recovered/not resolved.   It was unknown if the reporter considered the shingles and rash to be related to Shingrix.     Additional Information: GSK Receipt Date: 10-Oct-2022 Reporter's Comments: The patient received the first dose of the shingles vaccine a few years ago from reporting and not sure on the exact date. The patient got shingles in August but still had the rash now, and the patient would like to know when they could get the vaccine. The patient was now looking to get the second dose. The reporter did not have the date of the first vaccine dose, lot number or expiration date as it was administered at a different facility. The reporter consent to follow up via postal. Additional Supportive Information: Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. Note: Suspect vaccine name Shingrix was mentioned in structure field hence conservatively Shingrix was coded instead of shingles vaccine.
Patient called 10/25/19 to report a stabbing pain when he lifts his arm above his head. He said it is not exactly sore still but has this strange stabbing pain when he moves his arm in a certain way. The patient was advised to ice the arm and take ibuprofen or acetaminophen. If the pain persisted over the week-end the patient is to reach out to a medical provider. Currently the patient is without a primary care provider. Patient will follow up with the pharmacy after the week-end.
Symptoms: chills, fever (up to 101), headache, nausea. Treatment: Rest, TLC. Outcome: 2.5 days later back to normal.
Vaccinated on 3/13/03. Had rash assoc with this vaccination, but no take. Revaccinated on 3/24/03. 7 days post vac, developed mottling of skin distant from vac site. Good take noted. 8 days post vac, still with mottling. Resolved over unknown number of days.
Reactive Arthritis in right knee; severe stiffness and swelling, which felt like severe tendinitis. It took approximately 4 weeks to resolve enough for vigorous exercise, with another couple of weeks before more intense exercise did not cause further stiffness and discomfort
Information has been received from a female consumer referring to herself. There were no concomitant medication, pertinent medical history and drug reactions/allergies. At unspecified times, the patient was vaccinated with doses one and two of GARDASIL 9 injection (dosage, route, lot# and expire date unknown). The patient had a blood test to determine pregnancy at an unspecified healthcare provider's office on 22-AUG-2016 because she was due for her third dose in GARDASIL 9 series. The blood test came back negative for pregnancy. The patient received her third dose in the GARDASIL 9 series on 23-AUG-2016. On 24-AUG-2016, she administered an unspecified home pregnancy test to herself. This home pregnancy test came back positive for pregnancy. The patient had a second blood test to determine pregnancy at her unspecified healthcare provider's office on 25-AUG-2016. This test confirmed her pregnancy. The last menstrual period and estimated date of delivery were unknown. No adverse events reported. The patient did not see medical attention and no treatment was given for the event. There was no lab diagnostics studies performed. Additional information has been requested
09/06/22 presents to Triage Center for "SROM" "40w1d" PMHx of "Hypothyroidism"
pt recv vax & devel an inj site rxn, characterized by redness, swelling, & pain;pt also exp knot & elevated temp around inj site;sx lasted @ least 1wk;this is one of six pt from this site to report adverse rxn;
I started with soreness in my arm that had the shot. Later in the day, I got a headache and body aches.  In the middle of the night, I woke up with chills, body aches, and could not sleep (felt very wired).  The next morning, I still had a headache and body aches, couldn't eat much, and felt like I was coming down with the flu.  I continued with my day like I normally would (went to work) and started to feel better towards  the later part of the afternoon.
became tired & achy next day;could hardly get through work 2 days later;by 24 missed work & stayed in bed for a week;scary;so very tired & achy;took lots of pain reliever for aches;seen by MD;back to work on 31OCT97;
No addiitional AE were reported; Office manager reported that a patient received an improperly stored VARIVAX that was reconstituted with properly stored sterile diluent.; This spontaneous report has been received from office manager, regarding to a patient of unknown gender and age. The patient's concomitant therapies, historical conditions and concurrent conditions.  On 15-APR-2022, the patient was vaccinated with first dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) (lot # U025791 has been verified to be valid, expiration date 19-AUG-2023) (dose regimen, route of administration and anatomical location were not reported) with properly stored sterile diluent (manufacturer unknown) (lot# and expiration date were not provided) for prophylaxis. Not adverse events (AE) were reported, and no further information was provided.  Additionally, it was reported that the varicella virus vaccine live (oka/merck) (VARIVAX)underwent a temperature excursion of 6 Fahrenheit (°F) up to 14 °F for 15 minutes and 14 °F up to 46 °F (average temperature 34.93 °F) for 1 hours and 15 minutes (product storage error). There was no previous temperature excursion.
Felt funny; fast heartbeat; flushing; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of   in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure abnormal and Blood cholesterol abnormal.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
At night time, felt my face getting hot and felt as if I had a fever.  4 days later, developed itchy rash under the armpits, and sides, lower stomach inner thigh near groin.
This spontaneous case was retrieved on 11-Oct-2021 from Vaccine Adverse Event Reporting System (VAERS) (reference number: 1701102-1), reported by other healthcare professional and concerned a 92-year-old, male patient. The patient's medical history and concomitant medications were not reported. On 15-Sep-2021, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, MF59; dose: reported as one, route of administration: intramuscular and anatomical location: right arm) for unknown indication. The batch number reported was 312828. On the same day, after receiving Fluad Quadrivalent, the patient developed a lump at the injection site and was bleeding profusely. After a few minutes of applied pressure, the patient stopped bleeding. The lump was still present when the patient left facility. On the same date, the patient recovered from the event of 'vaccination site haemorrhage'. At the time of initial reporting, the outcome of the event of 'vaccination site lump' was unknown. The reporter did not provide a causality assessment. This case was assessed as non-serious. Company comment: A 92-year-old, male patient was vaccinated with the suspect product Fluad Quadrivalent. On the same day after vaccination the patient developed a lump at the injection site and was bleeding profusely. Information regarding the underlying medical history and concomitant medications has not been provided. Causality is assessed as possibly related based on plausible time relationship.; Sender's Comments: A 92-year-old, male patient was vaccinated with the suspect product Fluad Quadrivalent. On the same day after vaccination the patient developed a lump at the injection site and was bleeding profusely. Information regarding the underlying medical history and concomitant medications has not been provided. Causality is assessed as possibly related based on plausible time relationship.
Numbness and tingling of left arm/hand, chest pain, dizziness, shoulder trapezius pain, muscle pain, back, neck, shoulder, sweating, lightheaded. Treatment: Pain clinic, PCP, Neurosurgeon, Rheumatologist, Physical Therapy, Chiropractic. Follow up 7/6/05: Severe pain radiating down left arm with numbness and tingling, fibromyalgia, spinal stenosis, pinched nerves (neck), bone spurs, carpal tunnel. Chronic pain syndrome. Fibromyalgia, Spinalstenosis, bone spurs, carpal tunnel, left arm locks up, severe neck and back pain
nosebleeds, and they continued until about a week after the second shot. This was a different kind of nosebleed that sometimes get in dry win; nosebleeds, and they continued until about a week after the second shot. This was a different kind of nosebleed that sometimes get in dry win; This is a spontaneous report from a contactable consumer (patient). A 68-years-old female patient received bnt162b2 (Pfizer BioNTech), dose 1 via an unspecified route of administration on 08Apr2021 (Batch/Lot number was not reported) at the age of 68-years-old as DOSE 1, SINGLE, dose 2 via an unspecified route of administration, administered in Arm Left on 29Apr2021 12:30 (Batch/Lot Number: ewo175) at the age of 68-years-old as DOSE 2, SINGLE for covid-19 immunisation. The COVID-19 vaccine was administered in Pharmacy or Drug Store. Medical history included nosebleed, known allergies penicillin, Swiss cheese, sometimes latex; other medical history hypertension, overweight, otherwise pretty healthy for an old lady. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included losartan (LOSARTAN) ; levothyroxine sodium (LEVOTHYROXIN) ; vitamin b complex (B COMPLEX [VITAMIN B COMPLEX]) ; vitamin c [ascorbic acid] (VITAMIN C [ASCORBIC ACID]) ; colecalciferol (D3) ; tocopherol (E VITAMIN) and fish (as reported). Reported Event: 2 weeks  in Apr2021 after the first shot, the patient started getting nosebleeds, and they continued until about a week after the second shot. This was a different kind of nosebleed that she sometimes get in dry winter air. Much heavier (3 drops per 2 seconds...yes, she timed it), and it originated very close to the nostril, where winter bleeds never happened. She had 2 to 5 nosebleeds per day, and was able to stop them by applying pressure near the bottom of nose. If she sneezed, yawned, or entered the shower, it started again. Not enough space in the "Medications" space to add fish oil and sometimes a baby aspirin. But she quit taking the aspirin until a week after the nosebleeds stopped. The event was reported as non-serious. No treatment was received for event. No covid tested post vaccination. The event outcome was recovered on an unknown date. Since the vaccination, the patient has not been tested for COVID-19.  The lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.
Screaming, poor color, perfusion with same cyanosis very irritable, pulse ox 98/148 8 infants Tylenol 1:45AM until approx 2:30PM
Sore throat, low grade fever initially then temp went up to 102, headache, vomiting and abdominal pain.
2 days since vaccination, inflammation/burning intensely/itchiness/redness/headache.
Left arm c/o swollen and area where admin. hot. Was given Clindamycin 300mg TID x 7 days.
3 days p/vax pt devel hives; This was the 1st shot in the Typhoid vax series; The reporter felt the rxn may have bben due to yellow fever vax;
About 30 minutes after the booster shot (i had the first 2 shots with no side effects) I got very dizzy, couldn't concentrate.  It felt like i had been drinking, I had not had anything to drink before or after the shot other than water.  It lasted for about 3 hours and then went away.
no adverse events; incorrect product storage; This spontaneous report was received from a nurse concerning a 4-year-old patient. The patient's concurrent conditions and medical history, as well as concomitant medications, were not reported.  On 25-MAR-2021, the patient was vaccinated with an improperly stored measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (lot # T030479, expiration date 03-JUL-2022) at a dose 0.5 milliliter for prophylaxis, which had a temperature excursion of 8 degree Fahrenheit for 15 minutes. the reporter stated that the temperature excursion was not detected by a data logger and that the vaccine had no previous temperature excursions. No additional adverse event were reported.
Pt is a 79 y.o. female with past medical history coronary artery disease (status post CABG 15 years ago, stress test unremarkable in 6/2021) , hypertension and hyperlipidemia who presented to ER complaining of general weakness and fatigue.  The patient reported having the following symptoms for the last couple weeks including fever up to 102 (improved with Tylenol), chills, loss of taste, dry cough, shortness of breath, chest tightness and weakness.  She reported that all his symptoms resolved except for the loss of taste and weakness.    She went to her doctor couple weeks ago and was given amoxicillin for 5 days for possible sinus infection which she completed 3 days of it and stopped it due to gastric upset.  Five days ago, she went again to have doctor due to recurrent symptoms.  This time she was tested for COVID and that this came back positive.  She was prescribed prednisone for 5 days and Z-Pak for 5 days (completed 4 days ordered).  # COVID-19 Patient with symptoms for the last 2 weeks All symptoms resolved except loss of taste and fatigue She is currently nonhypoxic  She completed 4 days of Z-Pak and prednisone as OP TSH 2.57 and free T4 1.5 Impression:  Debility is likely in postviral settings (COVID-19 infection)  Plan:  - Improved with hydration and nausea meds.  - admitted with observation status - no need for remdesivir or dexamethasone  - contact, eye and N-95 isolation - PT/OT  Patient was discharged Disposition: Home Condition: Stable (s/sx potential problems absent or manageable)
Information has been received from a physician concerning a 2 year old male who on 26-JUN-2008 was vaccinated with ATTENUVAX vaccine (Enders-Edmonston). On 04-JUL-2008 the patient experienced fever and measles type rash. It was reported that the patient has not recovered. Unspecified medical attention was sought. There was no product quality complaint. Additional information has been requested
I had overeaten that day and I had terrible abdominal pain, bloating, & vomiting. I never have had these symptoms after overeating. I thought that I may be having a heart attack. I took a walk around the block, and it did not help. I had abdominal pain, flank pain, chills, fever, vomiting and shortness of breath. I went to the emergency at 5 am. I also had a low heart rate which scared them. They ran a lot of tests and provided a diagnosis of Non-Intractable Vomiting with nausea unspecified vomiting type and Vagal Bradycardia. I was told to see my general practitioner and advised me to get a stress test done. The symptoms lasted for about 12 hours and then I completely recovered back to my normal state. I did complete the heart stress test on 01/13/2022. The results were normal.
patient received an expired vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient received an expired vaccine) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (patient received an expired vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (patient received an expired vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.  Company comment include This case concerns a patient with unknown age and gender with no reported medical history , who experienced Non-serious event of Expired product administered which occurred on an unknown date and with an unknown dose of mRNA-1273 vaccine ( Moderna Covid 19 Vaccine ) . The re-challenge is not applicable in relation to the nature of the event. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.; Sender's Comments: This case concerns a patient with unknown age and gender with no reported medical history , who experienced Non-serious event of Expired product administered which occurred on an unknown date and with an unknown dose of mRNA-1273 vaccine ( Moderna Covid 19 Vaccine ) . The re-challenge is not applicable in relation to the nature of the event. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.
Patient arrived for her second dose on 3/8/21.  She showed a picture of her arm on her phone.  States 10 days after receiving the first dose she developed a big purple bruise at the injection site.
Immediate local reaction - spread to upper arm, hot to touch, glands swollen under arm where received shot - reaction on right arm where received PPSV - no reaction to Flu.
fever, chills, headache, body aches, pain at site of injection, neck pain for the whole following day of injection. started getting better and  no fever on second day after injection.
Breakthrough case admission after three vaccines: Moderna 1/8/2021 batch/lot# 026L20A; Moderna 2/5/2021 batch/lot# 012L20A; Moderna 11/23/2021 batch/lot# 012H21B.
This spontaneous report as received from a physician refers to a patient of unknown age and gender. No concurrent conditions, medical history and concomitant medications were reported. On an unknown date in March of 2015, the patient was administered the first dose of ZOSTAVAX (dosing details, lot# and expiry were unknown) and the second dose of ZOSTAVAX was administered on 09-MAR-2016. No adverse effects were reported. There were no product quality complains (PQC) involved. Additional information is not expected as the reporter did not wish further contact.
The first test was on 3/10/21, 5 days after the firstvaccine dose, where my PSA was 6.05. On the second test on 4/21/21, almost 4 weeks after the second dose, it was 6.65/elevated PSA levels; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 05Mar2021 at 12:15 (at the age of 68-years-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 26Mar2021 at 11:15 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. Medical history included moderate prostate enlargement and known allergy to penicillin. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included MULTIVITAMIN, PROBIOTIC, FISH OIL, MAGNESIUM, CHONDROITIN, GLUCOSAMINE, GINGER ROOT EXTRACT, and VITAMIN D3, all for unknown indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient reported possible vaccine effect Higher PSA test results following each COVID vaccine dose.  It was reported that the PSA in Oct2020 was 4.7, which was normal for patient's age (68), and had been around this level for the past several years. The patient recently had blood tests done for two different insurance applications. The first test was on 10Mar2021 at 12:00, 5 days after the first vaccine dose, where his PSA was 6.05. On the second test on 21Apr2021, almost 4 weeks after the second dose, it was 6.65. None of the symptoms he had for his moderate prostate enlargement had changed. The patient though this would be worth reporting in case other reports of elevated PSA levels had been made. He would very much like to know if other people had reported this, so that the patient could make the case with the insurance company that the higher PSA was likely due to the vaccine and not an indication of a potential for prostate cancer. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the elevated PSA levels was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Information has been received from a physician concerning a 3 month old HIV positive patient who was vaccinated with a first oral dose of Rotateq. One week post vaccination the patient experienced rotavirus gastroenteritis (rota test performed). Unspecified medical attention was sought. The patients outcome was not known. There was no product quality complaint involved. Additional information has been requested.
1st 24 hours:  arm pain, achy, headache, stuffiness and light cough Last 24 hours:  Stuffiness, heavy cough, bloodshot eye